Molecular structure of Cyclophosphamide, CAS Number: 50-18-0
Cyclophosphamide (CAS 50-18-0)
See product citations (18)
Alternate Names:
2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; Cyclophosphane; Cyclophosphamidum; Cyclophosphan; (RS)-Cyclophosphamide; (+-)-Cyclophosphamide; Clafen
Application:
Cyclophosphamide is an anti-proliferative agent that regulates Bax and Bcl-2 expression
CAS Number:
50-18-0
Purity:
≥90%
Molecular Weight:
261.09
Molecular Formula:
C7H15Cl2N2O2P
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cyclophosphamide has been reported to be an anti-proliferative agent that regulates Bax and Bcl-2 expression. This compound also inhibits ALDH1 (aldehyde dehydrogenase 1) through its degradation product acrolein. Cyclophosphamide is a nitrogen mustard analog. It undergoes activation through the enzyme cytochrome P450. Its mechanism of action involves the alkylation and cross-linking of DNA, thereby impeding DNA synthesis and leading to cell death. Additionally, Cyclophosphamide exhibits binding capabilities to proteins, hindering protein synthesis.
Cyclophosphamide (CAS 50-18-0) References
- Cyclophosphamide inhibits the development of diabetes in the diabetes-prone BB rat. | Sobel, DO., et al. 2000. Diabetologia. 43: 986-94. PMID: 10990075
- Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. | Voorhorst, MJ., et al. 2014. Anticancer Drugs. 25: 1211-4. PMID: 25144346
- Moderator's view: Cyclophosphamide in lupus nephritis. | Tesar, V. 2016. Nephrol Dial Transplant. 31: 1058-61. PMID: 27190357
- Dosage escalation of intravenous cyclophosphamide in cats with cancer. | Moore, AS., et al. 2018. Vet J. 242: 39-43. PMID: 30503542
- The Influence of Different Triazole Antifungal Agents on the Pharmacokinetics of Cyclophosphamide. | Cai, T., et al. 2020. Ann Pharmacother. 54: 676-683. PMID: 31893943
- The Protective Effect of Testosterone on the Ovarian Reserve During Cyclophosphamide Treatment. | Yoo, M., et al. 2020. Onco Targets Ther. 13: 2987-2995. PMID: 32308430
- LLLT enhance cyclophosphamide induced TRPM2 channel activation in human colon cancer cells. | Guler, Y. and Ovey, IS. 2020. Bratisl Lek Listy. 1: 334-338. PMID: 32356430
- Phase I dose escalating study of oral cyclophosphamide in tumour-bearing cats. | Chan, CM., et al. 2020. Vet J. 258: 105450. PMID: 32564869
- Cyclophosphamide in treatment of tumefactive multiple sclerosis. | Fereidan-Esfahani, M. and Tobin, WO. 2021. Mult Scler Relat Disord. 47: 102627. PMID: 33246262
- Protective effect of myricetin, apigenin, and hesperidin pretreatments on cyclophosphamide-induced immunosuppression. | Berköz, M., et al. 2021. Immunopharmacol Immunotoxicol. 43: 353-369. PMID: 33905277
- The cytotoxicity of cyclophosphamide is enhanced in combination with monascus pigment. | Kurokawa, H., et al. 2021. J Clin Biochem Nutr. 69: 131-136. PMID: 34616104
- The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide. | Chen, L., et al. 2022. Recent Pat Anticancer Drug Discov. 17: 195-203. PMID: 34758719
- Biodegradation of cyclophosphamide and etoposide by white rot fungi and their degradation kinetics. | Yadav, A., et al. 2022. Bioresour Technol. 346: 126355. PMID: 34798252
- The Immunomodulatory Effects of Phellodendri Cortex Polysaccharides on Cyclophosphamide-Induced Immunosuppression in Mice. | Cheng, Y., et al. 2021. Evid Based Complement Alternat Med. 2021: 3027708. PMID: 34840584
- Incidence of Sterile Hemorrhagic Cystitis in Dogs Treated with Cyclophosphamide and Low-Dose Furosemide. | Iwaki, Y., et al. 2022. J Am Anim Hosp Assoc. 58: 85-90. PMID: 35195711
Inhibitor of:
4933413G19Rik, AL, ALDH1, B lymphocytes, B930041F14Rik, C10orf28, C11orf91, C4 A, C6orf10, CD22, CD79B, CECR1, CIZ1, COL18A1, COL4A6, CTAGE3, CXorf48, CYP2B6, Cyp4f13, CYP4F2, DLEU7, DNA pol μ, DSPG3, FcRH4, GAL3ST1, gametogenetin, Gight chain, GLTPD1, Gm597, GTSF1L, HEXB, HLA-HB1, HN1L, Ig κ, Ig λ, Ig λ chain V4A, Ig λ light chain, IgA, IgA2, IgAight chain, IgD Chain C, IgG, IgG κ light chain, IgG Fab fragment, IgG2, IgG2c, IgG4, IgH-VJ558, IgHg, Igk-C, IgM, KIR2DL1, KIR3DL3, LOC441052, LOC642366, LOC643749, LOC645323, LOC645485, Ly-49G, Ly6G6e, MIG, Olr203, Perlecan, PGBD3, Placental RNase inhibitor, Plasma Cell, RASSF10, Rheumatoid Factor, SPATA16, SPATA9, SPNR, T-cell receptor Vδ 1, T-cell receptor Vδ 2, TCR α, TCR δ, TIGA1, TPO, TRAG-3, Trav12-1, Trav12n-1, Trav6d-5, Txl-2, VMO1, and WC1.Activator of:
ΔN p63, 4931417G12Rik, Ada, APOBEC3B, ASAH2C, BAGE3, BCMA, Bu-1a, CPSF3, CTAGE4, DnaJA2, Drosophila axons, FCRLM1, fizzy-related protein, Forssman Antigen, Ig λ chain, Mec3, NPM2, Pdcd-1L2, POTE14, RAP80, SH2D1A, SSAT, SSX3, SSX4B, SSX5, SSX6, SSX7, SSX8, and SSX9.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cyclophosphamide, 50 mg | sc-361165 | 50 mg | $76.00 | |||
Cyclophosphamide, 100 mg | sc-361165A | 100 mg | $143.00 | |||
Cyclophosphamide, 500 mg | sc-361165B | 500 mg | $469.00 | |||
Cyclophosphamide, 1 g | sc-361165C | 1 g | $775.00 |